http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2185136-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28ecb9d2655209cb54a6fcae204d4cba
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
filingDate 1995-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e82a6e140b6ffd1c22be4d8a4f7e91ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9657004583fc274af60c55207ee6c109
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52e7ef306a67af0bca220e93346f5e43
publicationDate 1995-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2185136-A1
titleOfInvention New use of quinoline-3-carboxamide compounds
abstract The use of an antiinflammatory bowel disease quinoline-3-carboxamide compound comprising structure (I), optionally with substituents for the hydrogen atoms shown: (H1-9), or a pharmaceutically acceptable salt of said compound where: (a) -------- represents that there are two conjugated double bonds between the atoms comprised by the dashed line; (b) X1 and X2 are separately selected from an oxygen atom or an NH9 group, said X1 and X2 being bound by a single bond to the ring when attached to H7 or H8 and by a double bond when not bound to H7 or H8; (c) H1-9 are hydrogens with the provision that H9 is only present when at least one of X1 and X2 is the NH9 group; (d) H7 and H8 are hydrogens that are attached to different atoms selected among X1, X2 and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for treating inflammatory bowel disease or conditions associated with this disease. Also described are methods for treating inflammatory bowel disease or conditions associated with this disease in which methods the above compounds are administered to a living body. Particularly preferred compounds are N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or a salt thereof.
priorityDate 1994-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5339
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54676478
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID515951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15561101
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426079160
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457623688
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5336
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396227
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494150
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54675840
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407194062
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457484072
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421969900
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579757
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451

Total number of triples: 34.